Dantrolene sodium in spasticity. Long-term administration in children

G. E. Molnar, L. A. Evangelista, R. Kathirithamby

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


This article reports on 27 children with spasticity caused by cerebral palsy and other nonprogressive neurologic conditions who received dantrolene sodium for a mean period of 16 months, with a range of 4 to 41 months; age varied from 2 to 14 years at the onset of treatment. All children showed some degree of favorable change, although statistically significant improvement could be demonstrated only in certain neurologic signs. Dosage ranged from 1 to 8.5 mg per kilogram per day. On long-term treatment, the usual daily dose was 2 to 5 mg per kilogram. Clinical side-effects were mild and transient. Laboratory examinations showed temporary abnormality of liver-function tests in six children. In an additional case, persistent abnormal test findings led to discontinuation of treatment.

Original languageEnglish (US)
Pages (from-to)1233-1237
Number of pages5
JournalNew York State Journal of Medicine
Issue number8
StatePublished - Dec 1 1978

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Dantrolene sodium in spasticity. Long-term administration in children'. Together they form a unique fingerprint.

Cite this